Lilly's weight loss drug makes a major breakthrough! Research shows that terlipressin can significantly reduce the risk of heart failure.

A trial result shows that the effective ingredient tirzepatide in Zepbound, a heavy-weight weight-loss drug, and Mounjaro, a diabetes treatment drug under Lilly (LLY.US), can significantly reduce the risk of heart failure worsening in overweight adults with heart failure preserved ejection fraction (HFpEF). In the phase III study called "SUMMIT", tirzepatide reduced the risk of heart failure worsening in overweight adults with HFpEF by 38% and reduced the risk of hospitalization due to heart failure by 56% compared to placebo. Additionally, patients taking tirzepatide had an average weight loss of 15.7%, while those in the placebo group had an average weight loss of 2.2%. Currently, there is no specific treatment for obesity-related HFpEF in the United States. The above-mentioned study is the first conducted in obese patients with HFpEF to evaluate the reduction of heart failure events risk and improvement of function as primary endpoints. Data shows that tirzepatide demonstrated statistically significant improvements in both primary endpoints and met all key secondary endpoints. Furthermore, Lilly has submitted an application for tirzepatide for the treatment of obesity-related HFpEF to global regulatory agencies.